Ajanta gets US FDA approval for Topiramate ER Capsules
As per the settlement with the innovator, Ajanta can launch Topiramate on February 1, 2026 or earlier under certain circumstances
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Ajanta Pharma
Address by Guest of Honour
In his address to the audience, Satish Agarwal, President (Tech and Operations), Ajanta Pharma, said, “At the time of…
Ajanta Pharma lines up CAPEX of Rs 250 crores for current fiscal
It will largely go towards maintenance and some new expansions for the corporate office and some key expansions in the facility,…
Ajanta Pharma posts jump in consolidated PAT to Rs176.63 crores in Q3 FY2020-21
Ajanta Pharma has reported financial results for the period ended December 31, 2020.
The company has reported total income of…
Ajanta Pharma Q2 net profit dips 7 to Rs 116 crore
Income from operations rose to Rs 643 crore during the period under review, as compared with Rs 544 crore in the year-ago period
KEY NOTE ADDRESS: Molecule to market
Dr Ramesh Jhawar, President of Ajanta Pharma, and a veteran with over four and half decades of experience in the life sciences…
Ajanta Pharma’s total comprehensive income dips by 23% in Q1 FY 2018
Company posted profit after tax at Rs. 95 crores
Ajanta Pharma receives US FDA approval for migraine drug
Zolmitriptan tablets are part of an 'ever-growing portfolio' that the company has developed for the US market Ajanta Pharma has…
Ajanta Pharma posts Q4 and FY 2016 results
Revenue from operations grew 14 per cent at Rs 426 crores against Rs 372 crores in Q4 FY 2016
Ajanta Pharma gets US FDA nod for migraine pain relief drug
Ajanta Pharma USA is scheduled to launch the almotriptan malate tablets in the US shortly Ajanta Pharma has received final…